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Trained in nephrology from 1974 to 1976, I began to consider myself a geriatric specialist
beginning in 1983 when I compiled what I believe was the first subspecialty textbook of
geriatric medicine, Geriatric Nephrology and Urology [1]. I became board certified in geriatrics
by the American Board of Internal Medicine in 1988, several years later but now nearly 30 years
ago. In the 1990s, I helped to develop a Geriatric Assessment Program for Sioux Valley Medical
Center in Sioux Falls, South Dakota, a MEDRED (medication reduction) clinic program for
correction of polypharmacy [2] in rural South Dakota, and published original geriatric and
gerontology research. My clinical research included the identification of nutritional deficien‐
cies of the elderly [3] and the use of biomarkers such as brain natriuretic peptide (BNP) to
assist in the prevention of readmission to the hospital for elders with chronic congestive heart
failure [4]. My basic science research focused on the role of dietary control of obesity to slow
renal senescence [5, 6]. After 2000, I assisted in the founding and ongoing teaching effort of a
Fellowship in Geriatrics. Based on my dedication to the care of the elderly verified by the above
experiences, I feel justified in providing a brief summary of the most common clinical problems
I face daily in the year 2016 and summarize the importance of each of the chapters in this
collection to geriatric medicine from my perspective.
The most frustrating clinical problems I now frequently face in caring for elders include
intracranial bleeds due to falls in elders on new anticoagulants for atrial fibrillation, severe
hypoxemia in elders with pneumonia, recurrent advanced congestive heart failure in those
failing medical therapy, Clostridium difficile colitis refractory to oral antibiotics, acute renal
deterioration associated with multiorgan dysfunction in patients with pneumonia or heart
failure, morbid obesity resulting in pulmonary and hepatic dysfunction, and myelodysplasia
resulting in refractory pancytopenia. I give a brief explanation of the difficulty in managing
these problems and their relevance to chapters in this book.
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Devastating neurologic diseases that are common in the elderly include dementia and stroke,
which are difficult to prevent and unpredictable in occurrence. On the other hand, potentially
avoidable but even more difficult to manage neurologic catastrophes for elders are the
intracranial bleeds associated with falls [7]. The difficulty in controlling these bleeds is greater
when patients have been receiving therapy with antiplatelet therapy or anticoagulants,
especially the newer agents that are less readily reversible. Because of the high mortality of
patients with this problem and possible reversibility, I devote the largest part of this introduc‐
tion to details in managing this problem.
I start with a brief case which was so striking that I recall it frequently. A prominent attorney
and past president of the board of our health system was reasonably fit in his mid‐1980s tripped
and hit his head during a strenuous morning of exercise. He had been taking clopidogrel for
prior cardiac stent placement. After a brief delay, he collapsed and was in coma. He was found
to have severe intracranial hemorrhage, which was refractory to an attempt at correction by
transfusion of 10 units of platelets and administration of desmopressin (DDAVP) in the dose
of 0.3 g/kg. Bleeding continued, and he did not survive.
The most common cause of death seen month after month as I sit in at our trauma morbidity
and mortality conference is the patient receiving warfarin for atrial fibrillation who developed
a subdural or other intracranial bleed after a fall. Warfarin must be reversed to lower the INR
less than 1.4 in these cases with as many units of fresh‐frozen plasma as needed or infusion of
three‐ or four‐factor prothrombin complex concentrate [8]. I recommend the four‐factor
prothrombin complex in the following doses:
If the INR is 2 to <4, give 25 units/kg; maximum of 2500 units
If the INR is 4–6, give 35 units/kg; maximum of 3500 units
If the INR is >6, give 50 units/kg; maximum of 5000 units
Recently, reversal of the factor Xa and direct thrombin inhibitors has become available [14].
Idarucizumab is now available for the reversal of dabigratan (i.e., trade name Pradaxa), the
direct thrombin inhibitor. The dose should be 5 g intravenously (administered as two separate
2.5‐g doses of no more than 15 min apart).
The factor Xa inhibitors include rivaroxaban (trade name, Xarelto) and epixaban (trade name,
Eliquis). A reversal agent for factor Xa inhibitors is in development (andexanet alfa). It appears
to act within minutes and persist for 2 h after intravenous administration of a dose of 400 (for
apixaban) or 800 mg (for rivaroxaban). It may also be necessary to follow a bolus with a 2‐h
infusion of 4 mg/min (for apixaban) or 8 mg/min (for rivaroxaban). A review of some of the
other common iatrogenic problems due to medications is presented in a chapter on “geriatric
assessment” and a chapter on “polypharmacy”.
Community‐acquired pneumonia (CAP) has a yearly rate of disease of 5 per 1000 population
and a mortality of 13.6%. Several cases that require ICU admission have mortality as high as
36% which increases even higher for each decade above 60 years of age [9, 10]. The problem is
made worse by the emergence of organisms resistant to frequently used antibiotics such as
methicillin‐resistant Staphylococcus aureus or MRSA. Newer life‐support techniques for
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managing severe hypoxia have been developed, which include pronation, extracorporeal
membrane oxygenation, nitric oxide administration, and intravenous or inhaled therapy with
prostaglandins. Details of each of these expensive, often invasive techniques are beyond the
scope of this chapter. However, a daily question facing physicians caring for elders with severe
hypoxia is whether these rescue life‐support therapies should be made available to the
advanced age groups. The chapter on ethics in this collection speaks about this issue.
Congestive heart failure remains one of the most common conditions requiring hospital
admission. Newer strategies for prevention and management have exploded in the past
30 years. Angiotensin blockade, b‐blockers, statins, very powerful diuretic combinations,
newer inotropes, intraaortic balloon pumps, venoarterial extracorporeal membrane oxygena‐
tion (VA ECMO), and commercial availability of ventricular assist devices (VADs) illustrate
the vast spectrum of management now available for this problem [11]. As mentioned previ‐
ously, biomarkers have become increasingly useful in diagnosis and management of patients
with heart failure. To distinguish cardiac from pulmonary causes of dyspnea, BNP has become
an important diagnostic tool, and the test can be used in titrating the management of heart
failure by repeating levels after diuresis. Other biomarkers used in managing patients with
breathlessness include ST2 (an interleukin released in heart injury and stretch) and higher
sensitivity troponin, which are both strong predictors of mortality. Finally, procalcitonin is
used in such patients to diagnose concomitant pneumonia which requires antibiotic therapy
[15, 12].
Gastroenterologic problems that I encounter the most include diverticulitis with and without
bowel perforation, colon cancer requiring resection, and C. difficile colitis (Cdiff). The last issue
may result from treating sepsis and infections associated with the first two topics and can be
considered an epidemic in the geriatric segment of our society. It now stands as the most
commonly reported nosocomial infection in the United States. While traditionally this infection
has been an inpatient issue, it is now being recognized as a growing concern in the outpatient
setting as well [13].
Some of these increased burdens are related to an epidemic strain that has been well described
in the literature since the early 2000s. With regard to age, there is no group of patients that has
experienced this problem with such dramatic consequences as the elderly. Those over the age
of 65 years have the greatest incidence of disease as well as the greatest mortality rate. In
addition, they demonstrate a higher recurrence rate, which not only contributes to a higher
likelihood of death but leads to substantial morbidity and reduced quality of life. This
recurrence rate is related to inadequate control of the infection due to a poor immune response
with insufficient anti‐toxin antibody production and inability to replenish a healthy microbiota
within the colon.
This infection is diagnosed with clinical suspicion and fairly simple laboratory testing. Most
patients have one or both of the dominant risk factors, which include recent contact with the
health‐care setting and recent use of antibacterial therapy. The dominant symptoms include
diarrhea and abdominal discomfort. While the white blood cell count can be normal with this
infection, it is usually elevated with more significant disease, and very high counts are not
uncommon and may even point a clinician toward this diagnosis. With regard to testing, stool
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can be sent for a variety of assays. Enzyme immunoassay that detects toxin has been utilized
for many years but has reduced sensitivity. The newer amplification tests for the toxin genes
were expected to help with this issue, but they may reveal positive results in a patient colon‐
ized with C. difficile who has other reasons for their symptoms. Thus, clinical suspicion and
pretest probability need to be adequate for testing to be ordered. Other important rules of
testing include only testing liquid stool, avoiding multiple consecutive tests, avoiding repeat
testing while on appropriate therapy, and avoiding a “test of cure” when symptoms have
resolved.
The management of this infection has been problematic due to the limited number of therapies
and the recurrent nature of the disease. Metronidazole (oral or intravenous) and oral vanco‐
mycin have been the two dominant therapies that have been utilized over the past several
decades. Metronidazole is now reserved for those with mild to moderate disease, while
vancomycin can be used across the spectrum, including those with severe disease. Combina‐
tion therapy is not well supported by data except in the critically ill population when impaired
gut motility may be a concern. Unfortunately, the recurrence rate for each of these therapies is
unacceptably high, and newer therapies are needed. One of those therapies may be fidaxomi‐
cin, which has shown a lower recurrence rate in clinical trials. While there have been concerns
about the cost of this drug in the past, it has been debated that the cost of the drug may be
more desirable than the cost of recurrent disease. Unfortunately, clear guidance does not
currently exist on this matter, and even fidaxomicin carries some risk of recurrence. Thus,
alternative therapy has been utilized that centers on a principle difference than eradication of
the organism. Fecal microbiota transplantation is being increasingly used in an effort to
replenish healthy bacterial flora within the colon and outcompete C. difficile, effectively
breaking the recurrent cycle of infection. This can be administered through a post‐pyloric
nasogastric tube, through enema, or via colonoscopy. The importance of avoiding future
antibacterial therapy should be stressed if this treatment is to have lasting effects for the patient.
As this disease poses great risk to elderly patients, the dominant approach should be preven‐
tion. Unfortunately, these patients are high utilizers of the health‐care system, and they are
often exposed to antibacterial therapy as well as sites within the system where the organism
may be acquired. Clinicians need to take great care when deciding if antibacterial therapy is
truly indicated for a given condition. Common conditions that are often treated with unnec‐
essary antibacterial therapy include upper respiratory tract infections, asymptomatic bacter‐
iuria, and skin conditions such as stasis dermatitis. Hopefully, with appropriate antibiotic
stewardship, as well as adequate infection control measures, the incidence of this disease
within this vulnerable population will fall. Further assistance may come with vaccine devel‐
opment, and clinical trials are currently ongoing.
Advances in dialysis and renal transplantation have led to wide availability of end‐stage renal
failure therapy offered to people of all ages [1, 6]. The financial impact has been staggering in
elderly individuals, especially considering that such life support is provided to outpatients
who are not very mobile and who have outlived members of their nuclear family. Hence, the
cost must also include transport to and from dialysis centers. Renal deterioration is often silent
until a final snowball of metabolic crises, which create life‐threatening illness and subsequent
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severe deconditioning. The chapter presented here on geriatric assessment deals with carefully
ferreting out serious problems in stubborn, stoic elders, which might be buried by a multi‐
plicity of other illnesses which create more symptoms.
Elders often suffer from a variety of cancers whose incidence increases with age. A particularly
frustrating and not uncommon hematologic problem is the patient with refractory anemia,
resistant leukopenia, and intractable thrombocytopenia. These may be the consequence of a
primary cancer, a side effect of cancer chemotherapy, or due to the problem of myelofibrosis.
Primary myelofibrosis is a myeloproliferative neoplasm in which there is ineffective erythro‐
poiesis and the bone‐marrow deposition of fibrous connective tissue.
Most patients present with anemia, marked splenomegaly, early satiety, and systemic symp‐
toms of severe fatigue, low‐grade fever, night sweats, bone pain, and weight loss. Essential
thrombocythemia and polycythemia vera can both undergo delayed disease transformation
into a fibrotic state resulting in secondary myelofibrosis. Allogeneic hematopoietic cell
transplantation is the only treatment modality with a curative potential in primary myelofib‐
rosis for which most patients will not be a candidate. Other treatments can only be used for
symptom management and will primarily consist of frequent transfusions. The patients
become weaker and weaker, develop pancytopenia, and often die of sepsis. Ethics again plays
a role in deciding how far to go with cancers and myelofibrosis, especially since treatments for
cancers are often poorly tolerated, and adding advanced life support to sustain their lives for
more of such therapy becomes a difficult decision for families and physicians more so than
patients who will frequently request a transition to palliation or comfort care.
Morbid obesity management has become a science of its own—bariatrics. The year 2016
commonly results in a requirement for two skill sets in clinical medicine, bariatrics, and
geriatrics. The bariatric geriatric patient is more susceptible to multisystem organ failure
and requires different pharmacology, different medical devices, and different nutritional
management of the frequent failure of lungs, heart, liver, and kidneys in these patients.
These patients frequently develop sleep apnea, edema, skin infections and ulcers, diabetes,
impaired mobility, hypertension, thromboembolism, pulmonary hypertension, cor pulmo‐
nale, and renal insufficiency. Pharmacokinetics of medication administration and nutrition
during illness are complicated and confusing as to whether to base them on actual or ideal
weight. When hospitalized, they require specialized beds, wheelchairs, and extra staff for
assisted transfers at an increased cost. Special scans (computerized tomography (CT) and
magnetic resonance imaging (MRI)) are often delayed or denied because of physical
constraints of the scanner opening and weight limits on the imaging tables. There is a
chapter in this collection on frailty in the elderly. The obese elder is frail but will not be
recognized for this impairment because of the stereotype that a small thin person is frail.
In the past 20 years, there has been a new component to the health‐care continuum, the long‐
term, acute‐care unit (LTAC). Elders and even younger patients often have a lesser set of
physiologic disturbances after hospital or ICU discharge but which persist for weeks or
months. They require additional time for healing, for resumption of activities of daily life, and
instrumental activities of daily life. They often require weeks of ongoing treatments for the
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reason for hospitalization such as antibiotics for infections, wound management requiring
ongoing debridement, enteral or parenteral nutrition, continued ventilator support by
tracheostomy, and even dialysis. They require additional physical therapy, speech therapy, and
occupational therapy to resume independent functional status. One of the chapters in this
collection describes the growth of this new additional component of the health‐care continu‐
um: home, primary care, hospital, ICU, back to the hospital, long‐term acute care, skilled
nursing facility, and then back home.
In summary, this introductory chapter points to the direction for those which follow. The
clinical problems I have described are often better diagnosed in a single visit by the tool of
Geriatric Assessment. The above problems require complicated medication combinations,
which require knowledge of pitfalls in initial boluses and maintenance dosing in the elderly
as covered in a chapter to follow. The lack of cardiac reserve in complicated illnesses in the
elderly can be monitored by biomarkers. The ethical dilemmas we face in the care of the most
seriously ill elders with problems such as the above have led to an exponential growth in
techniques of palliative care and hospice care including the legalization of physician‐assisted
suicide. Several chapters will deal with these moral, philosophical, and ethical issues. The
principles of managing patients over 60 have resulted in the creation of a field of clinical
specialists who can become board certified in Geriatrics. The anatomy, physiology, demo‐
graphics, and social issues of aging have likewise expanded a body of knowledge, which has
been identified as gerontology. This publication seeks to summarize several of the more
common clinical problems and their management which have come to the fore in the care of
elders in 2016.
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